Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to $27.2 million.

  • Tandem Diabetes Care's Net Cash Flow rose 105186.13% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 23421.04%. This contributed to the annual value of $9.1 million for FY2024, which is 10803.09% up from last year.
  • Tandem Diabetes Care's Net Cash Flow amounted to $27.2 million in Q3 2025, which was up 105186.13% from $8.9 million recorded in Q2 2025.
  • Tandem Diabetes Care's Net Cash Flow's 5-year high stood at $47.7 million during Q4 2022, with a 5-year trough of -$50.4 million in Q3 2023.
  • In the last 5 years, Tandem Diabetes Care's Net Cash Flow had a median value of $3.3 million in 2023 and averaged -$264842.1.
  • Within the past 5 years, the most significant YoY rise in Tandem Diabetes Care's Net Cash Flow was 105186.13% (2025), while the steepest drop was 268052.43% (2025).
  • Tandem Diabetes Care's Net Cash Flow (Quarter) stood at -$41.3 million in 2021, then surged by 215.5% to $47.7 million in 2022, then plummeted by 144.41% to -$21.2 million in 2023, then skyrocketed by 185.11% to $18.0 million in 2024, then soared by 51.03% to $27.2 million in 2025.
  • Its last three reported values are $27.2 million in Q3 2025, $8.9 million for Q2 2025, and -$13.8 million during Q1 2025.